Literature DB >> 32555331

Inhibition of p53 DNA binding by a small molecule protects mice from radiation toxicity.

Qingliang Li1, Rezaul M Karim2,3, Mo Cheng2, Mousumi Das1, Lihong Chen1, Chen Zhang4, Harshani R Lawrence2, Gary W Daughdrill5, Ernst Schonbrunn2, Haitao Ji2, Jiandong Chen6.   

Abstract

Transcription factors are attractive therapeutic targets that are considered non-druggable because they do not have binding sites for small drug-like ligands. We established a cell-free high-throughput screening assay to search for small molecule inhibitors of DNA binding by transcription factors. A screen was performed using p53 as a target, resulting in the identification of NSC194598 that inhibits p53 sequence-specific DNA binding in vitro (IC50 = 180 nM) and in vivo. NSC194598 selectively inhibited DNA binding by p53 and homologs p63/p73, but did not affect E2F1, TCF1, and c-Myc. Treatment of cells with NSC194598 alone paradoxically led to p53 accumulation and modest increase of transcriptional output owing to disruption of the MDM2-negative feedback loop. When p53 was stabilized and activated by irradiation or chemotherapy drug treatment, NSC194598 inhibited p53 DNA binding and induction of target genes. A single dose of NSC194598 increased the survival of mice after irradiation. The results suggest DNA binding by p53 can be targeted using small molecules to reduce acute toxicity to normal tissues by radiation and chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32555331      PMCID: PMC7398576          DOI: 10.1038/s41388-020-1344-y

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  40 in total

1.  Interaction between p53 N terminus and core domain regulates specific and nonspecific DNA binding.

Authors:  Fan He; Wade Borcherds; Tanjing Song; Xi Wei; Mousumi Das; Lihong Chen; Gary W Daughdrill; Jiandong Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-15       Impact factor: 11.205

2.  The regulatory domain stabilizes the p53 tetramer by intersubunit contacts with the DNA binding domain.

Authors:  Marco Retzlaff; Julia Rohrberg; Natascha Jennifer Küpper; Stephan Lagleder; Alexander Bepperling; Florian Manzenrieder; Jirka Peschek; Horst Kessler; Johannes Buchner
Journal:  J Mol Biol       Date:  2012-10-24       Impact factor: 5.469

3.  Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts.

Authors:  Xiaolei Zhang; Peibin Yue; Brent D G Page; Tianshu Li; Wei Zhao; Andrew T Namanja; David Paladino; Jihe Zhao; Yuan Chen; Patrick T Gunning; James Turkson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-23       Impact factor: 11.205

Review 4.  Small-molecule modulators of c-Myc/Max and Max/Max interactions.

Authors:  Thorsten Berg
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

Review 5.  Prospective therapeutic applications of p53 inhibitors.

Authors:  Andrei V Gudkov; Elena A Komarova
Journal:  Biochem Biophys Res Commun       Date:  2005-06-10       Impact factor: 3.575

6.  Rational design of selective small-molecule inhibitors for β-catenin/B-cell lymphoma 9 protein-protein interactions.

Authors:  Logan R Hoggard; Yongqiang Zhang; Min Zhang; Vanja Panic; John A Wisniewski; Haitao Ji
Journal:  J Am Chem Soc       Date:  2015-09-18       Impact factor: 15.419

Review 7.  p53 in health and disease.

Authors:  Karen H Vousden; David P Lane
Journal:  Nat Rev Mol Cell Biol       Date:  2007-04       Impact factor: 94.444

Review 8.  Drugging the p53 pathway: understanding the route to clinical efficacy.

Authors:  Kian Hoe Khoo; Khoo Kian Hoe; Chandra S Verma; David P Lane
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

Review 9.  Targeting transcription factors in cancer - from undruggable to reality.

Authors:  John H Bushweller
Journal:  Nat Rev Cancer       Date:  2019-09-11       Impact factor: 60.716

10.  Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53.

Authors:  Christopher D Wassman; Roberta Baronio; Özlem Demir; Brad D Wallentine; Chiung-Kuang Chen; Linda V Hall; Faezeh Salehi; Da-Wei Lin; Benjamin P Chung; G Wesley Hatfield; A Richard Chamberlin; Hartmut Luecke; Richard H Lathrop; Peter Kaiser; Rommie E Amaro
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  3 in total

1.  Proapoptotic Effect and Molecular Docking Analysis of Curcumin-Resveratrol Hybrids in Colorectal Cancer Chemoprevention.

Authors:  Gustavo Moreno-Q; Angie Herrera-R; Andres F Yepes; Tonny W Naranjo; Wilson Cardona-G
Journal:  Molecules       Date:  2022-05-28       Impact factor: 4.927

Review 2.  DNA and RNA Binding Proteins: From Motifs to Roles in Cancer.

Authors:  Ondrej Bonczek; Lixiao Wang; Sivakumar Vadivel Gnanasundram; Sa Chen; Lucia Haronikova; Filip Zavadil-Kokas; Borivoj Vojtesek
Journal:  Int J Mol Sci       Date:  2022-08-18       Impact factor: 6.208

3.  MUC3A promotes non-small cell lung cancer progression via activating the NFκB pathway and attenuates radiosensitivity.

Authors:  Yingming Sun; Xiaoge Sun; Chengcheng You; Shijing Ma; Yuan Luo; Shan Peng; Fang Tang; Xiaoli Tian; Feng Wang; Zhengrong Huang; Hongnv Yu; Yu Xiao; Xiaoyong Wang; Junhong Zhang; Yan Gong; Conghua Xie
Journal:  Int J Biol Sci       Date:  2021-06-16       Impact factor: 6.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.